Inclusion Criteria:

Histology and staging of disease:

- Newly diagnosed intrinsic pontine glioma documented by MRI and measurable in at least
one dimension

- Histology is not required for this study, tumour biopsy is not recommended General
conditions

- Age ≥ 3 years to ≤ 20 years, both gender

- Life expectancy ≥ 4 weeks

- Performance status ECOG ≥ 3 or Karnofsky/Lansky status ≥ 40%

- Adequate haematological, renal, and hepatic function Absolute leukocyte count ≥ 2.0 x
109/l Haemoglobin ≥ 10 g/dl Platelets ≥ 50 x 109/l Bilirubin total ≤ 2.5 x ULN
ALT/AST ≤ 5.0 x ULN Creatinine i. S. ≤ 1.5 x ULN

Prior/initial examinations (within 14 days prior to the start of therapy):

- Cranial MRI (estimation of index lesion)

- Clinical internal and neurological examination; body weight, height, surface,
Performance status by ECOG, Karnofsky or Lansky

- Blood cell count, blood gas analysis; serum analysis for electrolytes (Na, K, Ca,
Mg), chloride, phosphate, creatinine, BUN, AST, ALT, bilirubin, GGT, LDH, lipase,
total protein, CRP, blood sugar; coagulation test (Quick, PTT, TT); urinalysis

- EKG, echocardiography in case of positive cardiac history

- Pregnancy test in females of childbearing age Other criteria

- Planned day of first antibody application within 14 days after MRI

- Written and signed informed consent from patient and/or parents or legal
guardian(s)(s) after being informed

- Negative pregnancy test in females of childbearing age

- Treatment in a study centre

- Availability of the patient during the study treatment and the ability to comply with
the study plan

Exclusion Criteria:

- Pontine glioma as secondary malignancy

- Low grade brain stem glioma (i.e. focal, cervicomedullar, tectal brain stem glioma)

- Other severe underlying disease or pre-existing serious conditions which bear the
risk of an inadequate study treatment (e.g. severe mental retardation, severe
statomotoric retardation, severe cerebral palsy, congenital syndromes)

- Prior antineoplastic therapy, inclusively chemotherapy, immunotherapy, radiotherapy

- Prior administration of a recombinant human or mural antibody or known
hypersensitivity to antibodies

- Simultaneous antineoplastic therapy other than the study treatment

- Participation in another therapeutic study or experimental treatment involving the
underlying cancer disease

- Pregnancy, lactating mother and inadequate contraception in females and males of
childbearing age